3 active not recruiting, 2 completed, 2 recruiting, 1 terminated. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Active not recruiting 2, Completed 2, Recruiting 2 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow PYC Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle) PYC-001 - OPA1 Gene Mutation, Autosomal Dominant Optic Atrophy | Phase 1 / Phase 2 | Recruiting | PYC Therapeutics | 24 | 2025-09-30 | 2026-06-29 |
| A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001 VP-001 - Retinitis Pigmentosa 11, Retinal Degeneration | Phase 1 / Phase 2 | Active not recruiting | PYC Therapeutics | 17 | 2025-06-01 | 2026-05-29 |
| Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003 PYC-003 - Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 1 | Recruiting | PYC Therapeutics | 166 | 2025-04-07 | 2026-07-27 |
| SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew) PYC-001 - OPA1 Gene Mutation, Autosomal Dominant Optic Atrophy | Phase 1 | Active not recruiting | PYC Therapeutics | 18 | 2024-10-31 | 2026-09-17 |
| MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby) VP-001 - Retinitis Pigmentosa 11, Retinal Degeneration | Phase 1 | Completed | PYC Therapeutics | 6 | 2024-06-13 | 2026-05-29 |
| Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation Autosomal Dominant Optic Atrophy, Optic Atrophy, Autosomal Dominant | Terminated | PYC Therapeutics | 1 | 2024-02-28 | 2025-03-14 | |
| SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects VP-001 - Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy | Phase 1 | Completed | PYC Therapeutics | 17 | 2023-04-20 | 2026-05-29 |
| Natural History of PRPF31 Mutation-Associated Retinal Dystrophy Retinitis Pigmentosa, Eye Diseases, Hereditary | Active not recruiting | PYC Therapeutics | 50 | 2022-07-07 | 2026-04-13 |
Retinal Dystrophies (4) · Optic Atrophies, Hereditary (3) · Optic Atrophy, Autosomal Dominant (3) · Eye Diseases, Hereditary (2) · Retinal Degeneration (2) · Retinal Diseases (2) · Retinitis Pigmentosa 11 (2) · Eye Diseases (1) · Polycystic Kidney, Autosomal Dominant (1) · Retinitis Pigmentosa (1)
Australia (5) · United States (5) · New Zealand (2) · Austria (1) · France (1) · Germany (1) · Hong Kong (1) · Netherlands (1)
Sreenivasu Mudumba, PhD (2) · Aishwarya Kundu (1) · Sreenivasu Mudumba (1)